|
KMID : 1161420200230060658
|
|
Journal of Medicinal Food
2020 Volume.23 No. 6 p.658 ~ p.666
|
|
|
Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients
|
|
Formisano Elena
Pasta Andrea
Cremonini Anna L.
Favari Elda
Ronca Annalisa
Carbone Federico
Semino Tommaso
Di Pierro Francesco
Sukkar Samir G.
Pisciotta Livia
|
|
|
Abstract
|
|
|
|
The guidelines for the treatment of dyslipidemias include the use of nutraceuticals (NUTs) in association with lifestyle modifications to achieve therapeutic goals. In NUT pill, different substances may be associated; in this study we investigated a combined NUT containing monacolin K (MonK)+KA (1:1), berberine (BBR), and silymarin. The aim of the study was to evaluate low-density lipoprotein cholesterol (LDL-C) reduction in 53 patients suffering from polygenic hypercholesterolemia, characterized by a low/intermediate cardiovascular risk calculated with SCORE algorithm. The effects on lipid profile of 2-month treatment with NUT containing MonK+KA (1:1), BBR, and sylimarin, were compared with Atorvastatin (ATO) 10?mg administrated in a matched control group. Serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and the cholesterol loading capacity (CLC) were determined at baseline and at the end of the study in NUT-treated group; variations were assessed. NUT was effective as lipid-lowering agent with a wide interindividual response variability (mean LDL-C from 170.8?±?19.9 to 123.8?±?20.0 with a change of ?47.0?±?21.5?mg/dL; P?
|
|
|
KEYWORD
|
|
|
Atorvastatin, berberine, cholesterol loading capacity, macrophage, monacolin K, nutraceutical, lipid-lowering treatment, PCSK9
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|